New targets for lymphoma treatment.
Johnson
P W M
PW
CR UK Clinical Centre, Cancer Sciences Division, University of Southampton, Southampton, UK.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D017322:Clinical Trials, Phase II as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006072:Gossypol / Q000031:analogs & derivatives / Q000627:therapeutic use; D006360:Heat-Shock Proteins / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008223:Lymphoma / Q000145:classification / Q000473:pathology / Q000628:therapy*; D016328:NF-kappa B / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome; D048069:Tumor Necrosis Factors / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D006360:Heat-Shock Proteins; D056572:Histone Deacetylase Inhibitors; D016328:NF-kappa B; D018124:Receptors, Tumor Necrosis Factor; D048069:Tumor Necrosis Factors; D013792:Thalidomide; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D046988:Proteasome Endopeptidase Complex; D006072:Gossypol; C028178:gossypol acetic acid